(NASDAQ: IPSC) Century Therapeutics's forecast annual earnings growth rate of N/A is not forecast to beat the US Biotechnology industry's average forecast earnings growth rate of 11.28%, and while it is not forecast to beat the US market's average forecast earnings growth rate of 32.52%.
Century Therapeutics's earnings in 2026 is -$109,788,000.On average, 8 Wall Street analysts forecast IPSC's earnings for 2026 to be -$92,040,586, with the lowest IPSC earnings forecast at -$97,599,598, and the highest IPSC earnings forecast at -$70,347,762. On average, 8 Wall Street analysts forecast IPSC's earnings for 2027 to be -$82,805,744, with the lowest IPSC earnings forecast at -$97,599,598, and the highest IPSC earnings forecast at -$53,236,144.
In 2028, IPSC is forecast to generate -$84,308,669 in earnings, with the lowest earnings forecast at -$133,090,361 and the highest earnings forecast at -$42,969,174.